Table 3.
Cox regression analysis of prognostic factors for overall survival in metastatic mixed/eosinophilic ccRCCs
| Variables | Univariate | Multivariate* | ||
| P value | HR | 95% CI | P value | |
| Age, years, (continuous) | 0.312 | |||
| Sex (female vs male) | 0.624 | |||
| Karnofsky performance status (≥80 vs <80) | 0.558 | |||
| IMDC risk | ||||
| Favorable risk | ― | |||
| Intermediate risk | 0.998 | |||
| Poor risk | 0.998 | |||
| Previous nephrectomy (yes vs no) | 0.256 | |||
| Sarcomatoid/rhabdoid features (absent vs present) | 0.220 | |||
| Necrosis (absent vs present) | 0.626 | |||
| WHO/ISUP grade (<G3 vs ≥G3) | 0.922 | |||
| Treatment group (TKI therapy vs ICI therapy) | 0.012 | 3.236 | 1.297 to 8.057 | 0.012 |
*The stepwise downward Cox regression model (final model).
ccRCC, clear cell renal cell carcinoma; ISUP, International Society of Urological Pathology; ICI, immune checkpoint inhibitor; TKI, tyrosine kinase inhibitor; IMDC, International Metastatic RCC Database Consortium.